A phase II study of Ad-SGE-REIC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223982

Enrollment

Registered

2018-07-19

Start date

2018-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant pleural mesothelioma

Interventions

investigational material(s) Generic name etc : Ad-SGE-REIC INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key inclusion criteria Pathologically confirmed malignant pleural mesothelioma which isunresectable Patients with one or more measurable disease ECOG PS<1 Patients who have adequate main organs function Patients who signed written informed consent

Exclusion criteria

Exclusion criteria: Key exclusion criteria Patients with simultaneous tumor and/or metachronaus tumor (excluding patients with them whose disease-free interval is over 2 years) Active infections Symptomatic brain metastasis requiring treatment Pulmonary fibrosis or interstitial pneumonia Cardiac effusion requiring treatment Comorbidities requiring systemic corticosteroid or an immunosuppressants

Design outcomes

Primary

Measure	Time frame
safety efficacy Progression free survival By Independent Central Review	—

Secondary

Measure	Time frame
safety efficacy Objective response rate, overall survival, safety, etc. By Independent Central Review	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026